1. Home
  2. DMRC vs MLYS Comparison

DMRC vs MLYS Comparison

Compare DMRC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMRC
  • MLYS
  • Stock Information
  • Founded
  • DMRC 2008
  • MLYS 2019
  • Country
  • DMRC United States
  • MLYS United States
  • Employees
  • DMRC N/A
  • MLYS N/A
  • Industry
  • DMRC EDP Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMRC Technology
  • MLYS Health Care
  • Exchange
  • DMRC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • DMRC 643.8M
  • MLYS 590.3M
  • IPO Year
  • DMRC N/A
  • MLYS 2023
  • Fundamental
  • Price
  • DMRC $31.37
  • MLYS $11.87
  • Analyst Decision
  • DMRC Buy
  • MLYS Strong Buy
  • Analyst Count
  • DMRC 3
  • MLYS 2
  • Target Price
  • DMRC $34.00
  • MLYS $30.00
  • AVG Volume (30 Days)
  • DMRC 136.3K
  • MLYS 255.3K
  • Earning Date
  • DMRC 11-14-2024
  • MLYS 11-11-2024
  • Dividend Yield
  • DMRC N/A
  • MLYS N/A
  • EPS Growth
  • DMRC N/A
  • MLYS N/A
  • EPS
  • DMRC N/A
  • MLYS N/A
  • Revenue
  • DMRC $39,044,000.00
  • MLYS N/A
  • Revenue This Year
  • DMRC $22.36
  • MLYS N/A
  • Revenue Next Year
  • DMRC $20.74
  • MLYS N/A
  • P/E Ratio
  • DMRC N/A
  • MLYS N/A
  • Revenue Growth
  • DMRC 19.09
  • MLYS N/A
  • 52 Week Low
  • DMRC $21.00
  • MLYS $6.06
  • 52 Week High
  • DMRC $43.43
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • DMRC 51.76
  • MLYS 41.32
  • Support Level
  • DMRC $27.16
  • MLYS $11.30
  • Resistance Level
  • DMRC $33.89
  • MLYS $13.06
  • Average True Range (ATR)
  • DMRC 1.94
  • MLYS 1.01
  • MACD
  • DMRC -0.22
  • MLYS -0.22
  • Stochastic Oscillator
  • DMRC 55.32
  • MLYS 14.43

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers, and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: